Ewha Womans University · 医学
Professor Kyubo Kim's research lab focuses on translational oncology and molecular mechanisms underlying cancer progression and treatment response, with a particular emphasis on head and neck, breast, and thyroid cancers. The lab investigates the biological regulation of secretory processes in epithelial and immune cells, exploring how molecular machinery like Munc18b influences disease pathogenesis and therapeutic outcomes. Clinical studies in the lab aim to optimize treatment strategies through improved staging, adjuvant therapy, and radiation techniques to enhance locoregional control and reduce treatment-related toxicity. The integration of molecular biology with clinical oncology defines the lab’s mission to improve patient survival and quality of life.
Figures are computed from collected data and may differ slightly.
Airway mucin secretion and MC (mast cell) degranulation must be tightly controlled for homoeostasis of the lungs and immune system respectively. We found the exocytic protein Munc18b to be highly expressed in mouse airway epithelial cells and MCs, and localized to the apical pole of airway secretory cells. To address its functions, we created a mouse with a severely hypomorphic Munc18b allele such that protein expression in heterozygotes was reduced by ~50%. Homozygous mutant mice were not viabl
Adjuvant chemoradiotherapy after curative resection can achieve a long-term survival in patients with EHBD cancer. Resection margin status, number of involved lymph nodes, and histologic differentiation are associated with locoregional relapse, distant metastasis, and overall survival, respectively. Distant metastasis was the major pattern of failure, possibly due to the increased locoregional control by use of adjuvant chemoradiotherapy. Intensification of systemic treatment is warranted.
In conclusion, this is the first study to show clinical and genetic evidence supporting the altered age cutoff point of 55 years in the AJCC 8th edition for PTC patients.
IMRT with SIB technique for locoregionally advanced NPC was feasible and effective regarding locoregional control and development of xerostomia, even after neoadjuvant chemotherapy. Definition of gross tumor volume by postchemotherapy extent of disease was also feasible.
In pT1-2N1 TNBC, breast conservation therapy achieved better locoregional recurrencefree, disease-free, and overall survival rates compared with mastectomy.
Adjuvant CRT is feasible and may enhance locoregional control in advanced-staged duodenal cancer after curative resection.
Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an acceptable in-field regional control rate in patients with SCL and/or IMN involvement. However, a higher RT dose to SCL or IMN RT was not associated with the improved DFS in these patients.
Our prognostic model identified high-risk BC patients with BM who might benefit from increased surveillance; if validated, our model could guide treatment selection for such patients. Patients with late BM might benefit from WBRT as initial local treatment.
The purpose of this study was to investigate the plan qualities of various treatment modalities for the radiotherapy of cutaneous Kaposi's sarcoma developed on the skin of the foot. A total of six virtual targets were generated on the skin of the foot in CT images. Five types of treatment plans were generated using photon beams (PB), electron beams (EB), high-dose-rate (HDR) brachytherapy with a Freiburg flap applicator, intensity-modulated radiation therapy (IMRT), and volumetric- modulated arc
Open papers in the app to read, cite, and organize with AI.
